$TGTX today announced the publication of preclinical data describing the unique immunomodulatory effects of their investigational therapy umbralisib

$TGTX is developing two therapies targeting hematological malignancies and autoimmune diseases

#stocks #biotech $IBB $APRE $AZN https://t.co/Ilko0pXVyu